Perimeter Medical Imaging AI Enters Systemwide Agreement with Intermountain Health
Rhea-AI Summary
Perimeter Medical Imaging AI (OTCQX: PYNKF) announced a systemwide agreement with Intermountain Health on Jan. 8, 2026 to enable deployment of Perimeter's S-Series OCT imaging technology for intraoperative tissue visualization.
The arrangement covers Intermountain Health locations including LDS Hospital in Salt Lake City and American Fork Hospital and permits any of Intermountain's 34 hospitals and 400 clinics across Utah, Idaho, Nevada, Colorado, Montana and Wyoming to acquire the technology. The agreement builds on a prior Development Support Agreement that provided a framework to evaluate the OCT technology and collect data to support Perimeter's AI algorithm development.
Positive
- Systemwide agreement with Intermountain Health covering 34 hospitals and 400 clinics
- Deployment enabled at LDS Hospital and American Fork Hospital
- Builds on prior Development Support Agreement to collect data for AI algorithm development
- Potential geographic expansion into Mountain West states where Perimeter is not yet deployed
Negative
- Press release discloses no purchase commitments, pricing, or revenue terms
- Initial deployments cited at two hospitals; broader acquisitions are permissive, not guaranteed
News Market Reaction
On the day this news was published, PYNKF gained 14.93%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Agreement paves the way for deployment of Perimeter's advanced intraoperative imaging technology across the Mountain West
"Perimeter's OCT technology is a valuable tool in my practice because it helps me visualize margins in real-time. This supports more informed surgical decisions," said Dr. Jennifer Tittensor, a breast surgeon at American Fork Hospital. "I'm thrilled that Intermountain Health and Perimeter have partnered to bring this technology to these hospitals."
Intermountain Health has 34 hospitals and 400 clinics in
"Intermountain Health has a long track record of delivering high-quality care throughout the Intermountain West, reaching patients across an exceptionally diverse set of urban and rural communities," said Perimeter CEO Adrian Mendes. "This collaboration opens the door for Perimeter to extend our technology into states where it has not yet been deployed, while supporting surgeons with advanced imaging tools that aim to enhance surgical decision-making and improve outcomes for the patients they serve."
This systemwide agreement builds on a previously announced Development Support Agreement between Perimeter and Intermountain Health. That agreement set a framework for the two organizations to evaluate the potential value of using Perimeter's OCT technology and to collect additional data to support the continued development of the Company's artificial intelligence (AI) algorithms.
About Intermountain Health
Headquartered in
About Perimeter Medical Imaging AI, Inc.
Based in
S-Series OCT Intended Use and Unapproved Uses
The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization with image review manipulation software for identifying and annotating regions of interest. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Annual Information Form for the year ended December 31, 2024, which is available on Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.
Contacts
Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: skilmer@perimetermed.com
Susan Thomas
Media Relations
Direct: 619-540-9195
Email: susan@endpointcommunications.net
Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: investors@perimetermed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-enters-systemwide-agreement-with-intermountain-health-302656856.html
SOURCE Perimeter Medical Imaging AI Inc.
